On November 6, 2023, Vaccitech, a clinical-stage biopharmaceutical company, underwent a significant transformation and rebranded itself as Barinthus Biotherapeutics. This name change was a strategic move to align with the company’s new focus on developing T cell immunotherapies for chronic infectious diseases, autoimmunity, and cancer. Barinthus Biotherapeutics has shifted its primary focus from vaccine development to the creation of innovative T cell immunotherapeutic candidates.
With a vision to revolutionize immunotherapies, Barinthus Biotherapeutics is determined to utilize its advanced suite of technologies, including the ChAdOx and MVA platforms. These cutting-edge platforms have proven to induce high levels of CD8+ cytotoxic T cells and CD4+ T cells, which are crucial in enhancing the effectiveness of immunotherapies.
Effective November 7, 2023, Barinthus Biotherapeutics will trade under the new ticker symbol ‘BRNS.’ This change signifies the company’s commitment to its new direction and its dedication to advancing the field of T cell immunotherapies.
https://beststocks.com/barinthus-biotherapeutics-pioneering-t-cell-i/
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.